Terapie celowane wysoko zróżnicowanych guzów neuroendokrynnych Review article
Article Sidebar
Published:
Dec 30, 2011
Keywords:
target therapy, carcinoid, neuroendocrine tumors
Main Article Content
Abstract
Neuroendocrine tumors (NETs) are a heterogenous group of malignancies with variable prognosis and response to treatment. Treatments for advanced neuroendocrine tumors were, until recently, rather limited. Surgery and liver directed therapy both have relatively limited impact, and systemic cytotoxic chemotherapy has minimal efficacy. Somatostatin analogs have been used for years to control disease and neuroendocrine symptoms, without cytotoxic intent. Promising results have emerged from studies evaluating radiolabeled somatostatin analogs and inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Szaluś N, Dziuk M. Terapie celowane wysoko zróżnicowanych guzów neuroendokrynnych. OncoReview [Internet]. 2011Dec.30 [cited 2024Nov.23];1(4(4):272-8. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/274
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Yao J.C., Hassan M., Phan A. et al.: One hundred years after „carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008; 26: 3063-3072.
2. Panzuto F., Nasoni S., Falconi M. et al.: Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 2005; 12: 1083-1092.
3. Schmidt C., Bloomston M., Shah M.H.: Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targed therapies. Oncogene 2011; 30: 1947-1505.
4. Sarmiento J.M., Que F.G.: Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 2003; 12: 231-242. \
5. Que F.G., Nagorney D.M., Batts K.P. et al.: Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg. 1995; 169: 36-42.
6. Sarmiento J.M., Heywood G., Rubin J. et al.: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J. Am. Coll. Surg. 2003; 197: 29-37.
7. Hodul P.J., Strosberg J.R., Kvols L.K. et al.: Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct; 15(4): 314-21.
8. Bloomston M., Al-Saif O., Klemanski D. et al.: Hepatic artery chemoembolization in 122patients with metastatic carcinoid tumor: lessons learned. J. Gastrointest. Surg. 2007; 11: 264-271.
9. Gupta S., Johnson M.M., Murthy R. et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005; 104: 1590-1602.
10. Kennedy A.S., Dezarn W.A., McNeillie P. et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am. J. Clin. Oncol. 2008; 31: 271-279.
11. Engstrom P.F., Lavin P.T., Moertel C.G. et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255-1259.
12. Sun W., Lipsitz S., Catalano P. et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 2005; 23: 4897-4904.
13. Bajetta E., Ferrari L., Procopio G. et al.: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann. Oncol. 2002; 13: 614-621.
14. Fjällskog M.L., Granberg D.P., Welin S.L. et al.: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107.
15. Ansell S.M., Pitot H.C., Burch P.A. et al.: A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543-1548.
16. Kaubisch A., Kaleya R., Haynes H. et al.: Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother. Pharmacol. 2004; 53: 337-340.
17. Kulke M.H., Kim H., Clark J.W. et al.: A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004a; 101: 934-939.
18. Kulke M.H., Kim H., Stuart K. et al.: A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004b; 22: 353-359.
19. Kulke M.H., Wu B., Ryan D.P. et al.: A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci. 2006c; 51: 1033-1038.
20. Ekeblad S., Sundin A., Janson E.T. et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-2991.
21. Kulke M.H., Stuart K., Enzinger P.C. et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006; 24: 401-406.
22. Sudhakar A., Sugimoto H., Yang C. et al.: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 2003; 100: 4766-4771.
23. Kulke M.H., Hornick J.L., Frauenhoffer C. et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15: 338-345.
24. Papotti M., Bongiovanni M., Volante M. et al.: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002 May; 440(5): 461-75.
25. Susini C., Buscail L.: Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006 Dec; 17(12): 1733-42.
26. Rinke A., Müller H.H., Schade-Brittinger C. et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 2009; 27: 4656-4663.
27. Schmid H.A., Schoeffter P.: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80(supl. 1): 47-50.
28. Kvols L., Wiedenmann B., Oberg K. et al.: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study [abstract]. J. Clin. Oncol. 2006; 24: 4082.
29. Valkema R., De Jong M., Bakker W.H. et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin. Nucl. Med. 2002; 32(2): 110-22.
30. Otte A., Herrmann R., Heppeler A. et al.: Yttrium -90 DOTATOC: first clinical results. Eur. J. Med. 1999; 26(11): 1439-47.
31. Waldherr C., Pless M., Maecke H.R. et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7,4 GBq 90Y-DOTATOC. J. Nucl. Med. 2002; 43(5): 610-6.
32. Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005 Apr 20; 23(12): 2754-62.
33. Kwekkeboom D.J., Bakker W.H., Kam B.L. et al.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 2003 Mar; 30(3): 417-22 [Epub 2003 Jan 9].
34. de Jong M., Breeman W.A., Valkema R. et al.: Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med. 005 Jan; 46(supl. 1): 13S-7S.
35. O’Donnell A., Faivre S., Burris H.A. III. et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 2008; 26: 1588-95.
36. Missiaglia E., Dalai I., Barbi S. et al.: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 2010; 28: 245-55.
37. Vignot S., Faivre S., Aguirre D. et al.: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005; 16: 525-537.
38. Yao J.C., Phan A.T., Chang D.Z. et al.: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008; 26: 4311-8.
39. Yao J.C., Lombard-Bohas C., Baudin E. et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J. Clin. Oncol. 2010; 28: 69-76.
40. Yao J.C., Shah M.H., Ito T. et al.: RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011; 364: 514-523.
41. Basu B., Sirohi B., Corrie P.: Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr. Relat. Cancer 2010; 17: 75-90.
42. Yao J.C., Phan A., Hoff P.M. et al.: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol. 2008; 26: 1316-1323.
43. Kulke M.H., Stuart K., Earle C. et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J. Clin. Oncol. 2006; 24: 4044.
44. Kulke M.H., Lenz H.J., Meropol N.J. et al.: Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008; 26: 3403-3410.
45. Raymond E., Nicoli-Sire P., Bang Y. et al.: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) [abstract 127]. Presented at the 2010 American Society for Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 22–24, 2010.
46. Phan A.T., Yao J.C., Fogelman D.R. et al.: A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J. Clin. Oncol. 2010; 28(15 supl.): Abstract 4001.
2. Panzuto F., Nasoni S., Falconi M. et al.: Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 2005; 12: 1083-1092.
3. Schmidt C., Bloomston M., Shah M.H.: Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targed therapies. Oncogene 2011; 30: 1947-1505.
4. Sarmiento J.M., Que F.G.: Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 2003; 12: 231-242. \
5. Que F.G., Nagorney D.M., Batts K.P. et al.: Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg. 1995; 169: 36-42.
6. Sarmiento J.M., Heywood G., Rubin J. et al.: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J. Am. Coll. Surg. 2003; 197: 29-37.
7. Hodul P.J., Strosberg J.R., Kvols L.K. et al.: Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct; 15(4): 314-21.
8. Bloomston M., Al-Saif O., Klemanski D. et al.: Hepatic artery chemoembolization in 122patients with metastatic carcinoid tumor: lessons learned. J. Gastrointest. Surg. 2007; 11: 264-271.
9. Gupta S., Johnson M.M., Murthy R. et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005; 104: 1590-1602.
10. Kennedy A.S., Dezarn W.A., McNeillie P. et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am. J. Clin. Oncol. 2008; 31: 271-279.
11. Engstrom P.F., Lavin P.T., Moertel C.G. et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255-1259.
12. Sun W., Lipsitz S., Catalano P. et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J. Clin. Oncol. 2005; 23: 4897-4904.
13. Bajetta E., Ferrari L., Procopio G. et al.: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann. Oncol. 2002; 13: 614-621.
14. Fjällskog M.L., Granberg D.P., Welin S.L. et al.: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107.
15. Ansell S.M., Pitot H.C., Burch P.A. et al.: A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543-1548.
16. Kaubisch A., Kaleya R., Haynes H. et al.: Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother. Pharmacol. 2004; 53: 337-340.
17. Kulke M.H., Kim H., Clark J.W. et al.: A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004a; 101: 934-939.
18. Kulke M.H., Kim H., Stuart K. et al.: A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004b; 22: 353-359.
19. Kulke M.H., Wu B., Ryan D.P. et al.: A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci. 2006c; 51: 1033-1038.
20. Ekeblad S., Sundin A., Janson E.T. et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 2007; 13: 2986-2991.
21. Kulke M.H., Stuart K., Enzinger P.C. et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol. 2006; 24: 401-406.
22. Sudhakar A., Sugimoto H., Yang C. et al.: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 2003; 100: 4766-4771.
23. Kulke M.H., Hornick J.L., Frauenhoffer C. et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res. 2009; 15: 338-345.
24. Papotti M., Bongiovanni M., Volante M. et al.: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002 May; 440(5): 461-75.
25. Susini C., Buscail L.: Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006 Dec; 17(12): 1733-42.
26. Rinke A., Müller H.H., Schade-Brittinger C. et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 2009; 27: 4656-4663.
27. Schmid H.A., Schoeffter P.: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80(supl. 1): 47-50.
28. Kvols L., Wiedenmann B., Oberg K. et al.: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study [abstract]. J. Clin. Oncol. 2006; 24: 4082.
29. Valkema R., De Jong M., Bakker W.H. et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin. Nucl. Med. 2002; 32(2): 110-22.
30. Otte A., Herrmann R., Heppeler A. et al.: Yttrium -90 DOTATOC: first clinical results. Eur. J. Med. 1999; 26(11): 1439-47.
31. Waldherr C., Pless M., Maecke H.R. et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7,4 GBq 90Y-DOTATOC. J. Nucl. Med. 2002; 43(5): 610-6.
32. Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al.: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005 Apr 20; 23(12): 2754-62.
33. Kwekkeboom D.J., Bakker W.H., Kam B.L. et al.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 2003 Mar; 30(3): 417-22 [Epub 2003 Jan 9].
34. de Jong M., Breeman W.A., Valkema R. et al.: Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med. 005 Jan; 46(supl. 1): 13S-7S.
35. O’Donnell A., Faivre S., Burris H.A. III. et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 2008; 26: 1588-95.
36. Missiaglia E., Dalai I., Barbi S. et al.: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 2010; 28: 245-55.
37. Vignot S., Faivre S., Aguirre D. et al.: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005; 16: 525-537.
38. Yao J.C., Phan A.T., Chang D.Z. et al.: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008; 26: 4311-8.
39. Yao J.C., Lombard-Bohas C., Baudin E. et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J. Clin. Oncol. 2010; 28: 69-76.
40. Yao J.C., Shah M.H., Ito T. et al.: RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011; 364: 514-523.
41. Basu B., Sirohi B., Corrie P.: Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr. Relat. Cancer 2010; 17: 75-90.
42. Yao J.C., Phan A., Hoff P.M. et al.: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol. 2008; 26: 1316-1323.
43. Kulke M.H., Stuart K., Earle C. et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J. Clin. Oncol. 2006; 24: 4044.
44. Kulke M.H., Lenz H.J., Meropol N.J. et al.: Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008; 26: 3403-3410.
45. Raymond E., Nicoli-Sire P., Bang Y. et al.: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) [abstract 127]. Presented at the 2010 American Society for Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 22–24, 2010.
46. Phan A.T., Yao J.C., Fogelman D.R. et al.: A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J. Clin. Oncol. 2010; 28(15 supl.): Abstract 4001.